Cargando…

Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis

OBJECTIVE: Therapies targeting B cells have been used in the clinic for multiple sclerosis (MS). In patients with relapsing MS, anti-CD20 therapy often suppresses relapse activity; yet, their effect on disease progression has been disappointing. Most anti-CD20 therapeutic antibodies are type I, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roodselaar, Jay, Zhou, Yifan, Leppert, David, Hauser, Anja E., Urich, Eduard, Anthony, Daniel C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931641/ https://www.ncbi.nlm.nih.gov/pubmed/33653962 http://dx.doi.org/10.1212/NXI.0000000000000975

Ejemplares similares

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration
por: Torres, Julia Baguña, et al.
Publicado: (2022)

Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2022)

Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis
por: Breakell, Thomas, et al.
Publicado: (2020)

Intrathecal CD8(+)CD20(+) T Cells in Primary Progressive Multiple Sclerosis
por: von Essen, Marina Rode, et al.
Publicado: (2023)

Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis?
por: Gupta, Sasha, et al.
Publicado: (2021)

Sera from Remitting and Secondary Progressive Multiple Sclerosis Patients Disrupt the Blood-Brain Barrier
por: Shimizu, Fumitaka, et al.
Publicado: (2014)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis
por: Sabatino, Joseph J., et al.
Publicado: (2019)

Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Elevated sCD40L in Secondary Progressive Multiple Sclerosis in Comparison to Non-progressive Benign and Relapsing Remitting Multiple Sclerosis
por: Wu, Qi, et al.
Publicado: (2021)

Involvement of cytotoxic Eomes-expressing CD4(+) T cells in secondary progressive multiple sclerosis
por: Raveney, Ben J. E., et al.
Publicado: (2021)

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues
por: Frisch, Esther S., et al.
Publicado: (2021)

Smallest Secondary Nucleation Competent Aβ Aggregates Probed by an ATP-Independent Molecular Chaperone Domain
por: Leppert, Axel, et al.
Publicado: (2021)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance
por: Ebadi, Maryam, et al.
Publicado: (2021)

Gut microbiota-dependent CCR9(+)CD4(+) T cells are altered in secondary progressive multiple sclerosis
por: Kadowaki, Atsushi, et al.
Publicado: (2019)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Secondary Progressive Multiple Sclerosis: New Insights
por: Cree, Bruce A.C., et al.
Publicado: (2021)

Accumulation of meningeal lymphocytes correlates with white matter lesion activity in progressive multiple sclerosis
por: Ahmed, Shanzeh M., et al.
Publicado: (2022)

Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain
por: Anthony, Daniel C, et al.
Publicado: (2014)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
por: Florou, Despoina, et al.
Publicado: (2020)

Role of CD20(+) T cells in multiple sclerosis: implications for treatment with ocrelizumab
por: Gingele, Stefan, et al.
Publicado: (2019)

Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
por: Roach, Charles A., et al.
Publicado: (2021)

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
por: Heming, Michael, et al.
Publicado: (2023)

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
por: de Sèze, Jérôme, et al.
Publicado: (2023)

An unusual presentation of hemiparesis: Rapidly progressing Streptococcal pneumoniae meningitis secondary to acute mastoiditis
por: Mathern, Ryan, et al.
Publicado: (2020)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
por: Beynon, Vanessa, et al.
Publicado: (2022)

Aseptic meningitis and hydrocephalus secondary to neurosarcoidosis
por: Pandey, Anmol, et al.
Publicado: (2021)

Aseptic Meningitis Secondary to Antibiotic Therapy
por: Negron-Diaz, Juan A, et al.
Publicado: (2021)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Lymphoid Aggregates in the CNS of Progressive Multiple Sclerosis Patients Lack Regulatory T Cells
por: Bell, Luisa, et al.
Publicado: (2020)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression
por: Law, Marco TK, et al.
Publicado: (2019)

The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruption
por: Lee, M W, et al.
Publicado: (2014)

Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
por: Margoni, Monica, et al.
Publicado: (2021)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Revisión de 20 casos de meningitis tuberculosa
por: Rincón Navarrete, Alba Argelia
Publicado: (1986)

Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles
por: Fong, Chloe C., et al.
Publicado: (2023)

Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis
por: DiSano, Krista D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p38n7aplr7p9cj0a0cblb4cgau